Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Operating Cash Flow
Cash generated by the company's core business operations during the period.
Avanos Medical, Inc.NYSE: AVNS
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow turns negative
Q1 FY2026 operating cash flow was -$12.3M, compared with $25.7M a year earlier. Trailing-twelve-month operating cash flow was $36.7M. Over 3 fiscal years it compounded at -6.3% a year.
Context
- Operating cash flow amounted to 10.7% of revenue in FY2025, down 4.0 pp from a year earlier.
- Operating cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly operating cash flow holds near -$12.3M or moves back toward the trailing-twelve-month quarterly average of $9.18M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 74.7M USD
- Year-over-year change
- -25.8%
- 4-year CAGR
- -3.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.7M | -25.8% |
| FY2024 | 2024-12-31 | 100.7M | +210.8% |
| FY2023 | 2023-12-31 | 32.4M | -64.4% |
| FY2022 | 2022-12-31 | 90.9M | +4.1% |
| FY2021 | 2021-12-31 | 87.3M | — |
Operating Cash Flow vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 operating cash flow of $36.7M is the 8th largest of the 11 companies compared; the peer median is $37.29M.
- Its year-over-year change of -72.7% is the 8th highest of 11, against a peer median of -17.0%.
- Operating cash flow amounts to 5.1% of revenue for AVNS, versus a peer median of 57.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $228.9M | +26.8% | +42.6% | 360.5% | |
| LTM Mar 2026 | $129.45M | -15.5% | +8.0% | 146.7% | |
| LTM Mar 2026 | $126M | -75.0% | +21.9% | 0.6% | |
| LTM Mar 2026 | $111.84M | -35.9% | -25.0% | 69.9% | |
| LTM Mar 2026 | $102.94M | +304.2% | — | 17.9% | |
| LTM Mar 2026 | $90.66M | -18.5% | -5.9% | 105.1% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $48.85M | +32.4% | +8.4% | 51.4% |
| LTM Mar 2026 | $36.7M | -72.7% | -6.3% | 5.1% | |
| LTM Mar 2026 | $25.72M | +128.0% | +14.0% | 63.3% | |
| LTM Mar 2026 | $7.3M | -134.3% | -27.4% | 3.6% | |
| LTM Apr 2026 | $2M | -103.3% | +35.1% | 0.2% | |
| Peer median (excluding AVNS) | $37.29M | -17.0% | +8.4% | 57.4% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.2M | 50.5M | (61.8M) | (392.1M) | (72.9M) |
| Depreciation & Amortization | 38.3M | 47.7M | 46.1M | 45.5M | 38.9M |
| Deferred Income Tax | (3.4M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.2M | 15.9M | 15.8M | 13.8M | 12.6M |
| Change in Working Capital | 26M | (24.3M) | (18M) | 35M | 9.8M |
| Accounts Receivables | (10.8M) | (24.7M) | 39M | (6.6M) | 30.9M |
| Inventory | 17.2M | (30.9M) | 4.7M | 39M | 200K |
| Accounts Payables | (11.9M) | 35.4M | (14.4M) | (900K) | 600K |
| Other Working Capital | 31.5M | (4.1M) | (47.3M) | 3.5M | (21.9M) |
| Other Non-Cash Items | 8M | 1.1M | 50.3M | 398.5M | 86.3M |
| Operating Cash Flow | 87.3M | 90.9M | 32.4M | 100.7M | 74.7M |
| Capital Expenditures | (21M) | (19.3M) | (17.8M) | (17.8M) | (31.6M) |
| Acquisitions (Net) | 0 | (116.1M) | 39.4M | (9.7M) | (28M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1M) |
| Investing Cash Flow | (21M) | (135.4M) | 21.6M | (27.5M) | (60.6M) |
| Debt Repayment | (50M) | 103.4M | (64.7M) | (33.6M) | (34.4M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 700K |
| Common Stock Repurchased | (11.5M) | (45.5M) | (19.1M) | (12.8M) | (3.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.2M | (1.2M) | (10.4M) | (2.7M) | 0 |
| Financing Cash Flow | (55.3M) | 56.7M | (94.2M) | (49.1M) | (37M) |
| Effect of Forex Changes | (4M) | (3M) | 200K | (4.1M) | 5M |
| Net Change in Cash | 7M | 9.2M | (40M) | 20M | (17.9M) |
| Free Cash Flow | 66.3M | 71.6M | 14.6M | 82.9M | 43.1M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.